Diagnostic Work-Up and Multidisciplinary Management of Steinert Muscular Dystrophy (Myotonic Dystrophy Type 1)
For suspected Steinert disease (DM1), confirm diagnosis with genetic testing for CTG repeat expansion in the DMPK gene (≥50 repeats diagnostic), followed by immediate cardiac and respiratory evaluation, as these systems pose the greatest mortality risk and require lifelong monitoring regardless of symptom severity. 1
Diagnostic Work-Up
Genetic Testing Algorithm
Primary diagnostic test: DMPK gene CTG repeat analysis using conventional PCR combined with triplet repeat-primed PCR (TP-PCR) 1
- Normal alleles: 5-34 CTG repeats (no disease)
- Variable alleles (premutation): 35-49 repeats (asymptomatic but risk of expansion in offspring)
- Fully-variable alleles (diagnostic): ≥50 repeats confirms DM1 1
Critical testing considerations:
- If single peak detected on PCR, particularly in the 35-49 range, perform Southern blot to exclude mosaicism (can be present down to ~10% levels) 1
- If patient has mild clinical symptoms but normal-range PCR result, Southern blot is mandatory to detect occult mosaicism 1
- Quantify exact CTG repeat number as it correlates with disease severity:
- 50-100 repeats: mild disease (cataracts, mild myotonia)
- 100-1000 repeats: classic disease (progressive weakness, cardiac/respiratory involvement)
- 1000-6000 repeats: congenital form (developmental delay, respiratory distress, high neonatal mortality) 1
Do not use short-read next-generation sequencing - it cannot reliably detect expanded alleles 1
Clinical Phenotyping
Look specifically for these multisystem features 1, 2:
Neuromuscular:
- Distal > proximal muscle weakness (facial, neck, distal limbs first)
- Grip myotonia (inability to release handshake)
- Facial weakness with temporal wasting ("hatchet face")
- Ptosis and ophthalmoparesis
- Dysarthria/dysphonia 3
Cardiac (present in ~80% of DM1 patients):
- Progressive conduction defects (first-degree AV block → complete heart block)
- Arrhythmias (atrial fibrillation/flutter, ventricular tachycardia)
- Dilated cardiomyopathy (less common than conduction disease) 2
Respiratory:
- Restrictive lung disease from respiratory muscle weakness
- Central hypoventilation
- Obstructive sleep apnea 3, 4
Other systems:
- Early cataracts (before age 50)
- Cognitive impairment/executive dysfunction (75.7% in pediatric series) 3
- Endocrine: diabetes mellitus, hypogonadism, thyroid dysfunction
- Gastrointestinal: dysphagia, constipation, cholelithiasis 3
Multidisciplinary Management Framework
Immediate Life-Threatening Priorities
1. Cardiac Evaluation (MANDATORY at diagnosis) 2, 5
- Baseline ECG and 24-hour Holter monitoring
- Echocardiogram
- Pacemaker/ICD implantation if: PR interval >240ms, any degree of AV block, bundle branch block, or ventricular arrhythmias
- Lifelong annual cardiac monitoring - sudden cardiac death can occur at any disease stage, not just severe phenotypes 6, 4
2. Respiratory Assessment (MANDATORY at diagnosis) 4, 5
- Pulmonary function tests (FVC, MIP/MEP)
- Polysomnography for sleep-disordered breathing
- Respiratory failure is the leading cause of death in DM1 4
- Consider non-invasive ventilation if FVC <50% predicted or symptomatic hypoventilation 3
Ongoing Multidisciplinary Care
Neurology (coordinating specialty):
- Monitor disease progression with standardized scales
- Screen for dysphagia periodically (aspiration risk) 5
- Manage myotonia (mexiletine if symptomatic, though muscle weakness typically more limiting)
Anesthesia precautions (CRITICAL):
- Pre-operative respiratory evaluation mandatory before any general anesthesia 5
- Increased risk of prolonged intubation, aspiration, malignant hyperthermia-like reactions
- Avoid depolarizing muscle relaxants (succinylcholine)
- Patients should carry medical emergency card 7
Genetics:
- Genetic counseling mandatory for all patients and at-risk relatives 1
- Autosomal dominant inheritance with 50% transmission risk
- Anticipation phenomenon: offspring typically more severely affected, especially with maternal transmission (congenital form almost exclusively from affected mothers) 1
- Prenatal/preimplantation genetic diagnosis options 1
Ophthalmology:
- Annual screening for cataracts (treatable cause of vision loss)
Endocrinology:
- Screen for diabetes, thyroid dysfunction, hypogonadism
Physical/Occupational Therapy:
- Maintain function, prevent contractures
- Fall prevention (falls cause significant morbidity) 4
Special Populations
Congenital DM1 (25 patients in pediatric series): 3
- Higher mortality in neonatal period from respiratory complications
- Survivors have static course initially, then progressive
- Severe intellectual disability common (75.7%)
- Exclusive skeletal deformities: talipes equinovarus, scoliosis
- Delayed independent ambulation
Pregnancy considerations:
- Maternal DM1 associated with polyhydramnios, preterm labor
- High risk of congenital DM1 in offspring
- Uterine atony risk at delivery
Emerging Therapies
Nucleic acid-based therapies targeting expanded DNA/RNA are in early clinical trials 6. Earlier intervention in mild/early disease may have greater disease-modifying potential than treatment of advanced disease where therapeutic window may be missed 6.
Common Pitfalls to Avoid
- Missing the diagnosis in mild phenotypes - many patients never see a neurologist and remain undiagnosed 6
- Failing to perform Southern blot when mosaicism suspected - PCR alone can miss expanded alleles 1
- Inadequate cardiac surveillance - sudden death can occur at any stage, even in mild phenotypes 6
- Underestimating anesthesia risk - always evaluate respiratory function pre-operatively 5
- Not recognizing thromboembolic risk - incidence 5.6 cases per 1000 patient-years, higher than expected 4